Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics Inc (NQ: UNCY )

0.8357 -0.1102 (-11.65%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Unicycive Therapeutics Inc

< Previous 1 2 Next >
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
Via TheNewswire.com
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via TheNewswire.com
Exposures Product Safety
CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive... 
Via Newsfile
Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
From Traders News Source
Via AccessWire
Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.